Summer Intern - Legal & Vendor Management

Karyopharm Therapeutics Inc.

Jan 23

Applications are closed

Internship
Full-time
Starts on May 26
Summer Internship
Legal

Requirements

Pursuing or completed studies in legal disciplines.
Basic Understanding of Contracts and Legal Language: Possess foundational knowledge of legal terms and contract principles.
Technology Proficiency: Demonstrate a good understanding of systems and technology relevant to legal and vendor management.
Interpersonal Skills: Exhibit strong interpersonal skills, fostering effective communication and collaboration.
Independence and Proactiveness: Showcase the ability to work independently and take proactive initiatives to contribute to team goals.
You have a strong interest in life sciences and are passionate about giving patients with cancer a chance to enjoy more of life’s precious moments.
You feel a strong connection with our ICARE values (Innovation, Courage, Alignment & Accountability, Resilience, and Energy)
You demonstrate enthusiasm for learning and a commitment to career development

Responsibilities

As a Summer Intern you will be working closely with Legal and Vendor Management and play a crucial role in supporting both departments by actively participating in contract system clean-up and learning about our contract review process. This internship offers a valuable opportunity to gain practical experience working with cross-functional teams in a dynamic professional environment.
Gatekeeper Clean-Up Tasks: Execute clean-up initiatives within the contract system to ensure accuracy and organization.
Simple Contract Review: Learn to review basic contracts and contributing to the legal evaluation process.
TMF Filings: Assist in the preparation and filing of Trial Master File (TMF) documents as part of the regulatory compliance process.
Ad Hoc Tasks: Tackle various ad hoc assignments to support the efficient functioning of Legal and Vendor Management.
Cross-Functional Collaboration: Work collaboratively with teams across different functions to verify the accuracy of information in Gatekeeper.

Karyopharm Therapeutics Inc.

Targeting Disease at the Nuclear Pore

Manufacturing & Electronics

Industry

201-500

Employees

2008

Founded Year

Mission & Purpose

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.